3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Stomach Neoplasms
5
Gastrointestinal Neoplasms
3
Pancreatic Neoplasms
2
Esophageal Neoplasms
2
Rectal Neoplasms
1
Neoplasms, Unknown Primary
1
Neoplasm Metastasis
1
Nasopharyngeal Carcinoma
1
Colonic Neoplasms
1
Bile Duct Neoplasms
1
Adenocarcinoma Of Esophagus
1
Adenocarcinoma
1
Interventions
Fluorouracil
37
Radiotherapy
31
Oxaliplatin
29
Cisplatin
28
Paclitaxel
24
Leucovorin
22
Irinotecan
19
Docetaxel
13
pembrolizumab
10
Capecitabine
10
Carboplatin
9
Radiation
8
Neoadjuvant Therapy
8
Cetuximab
8
Surgical Procedures, Operative
7
Folfox protocol
7
Chemotherapy, Adjuvant
6
Nivolumab
5
Gefitinib
5
Taxes
4
Erlotinib Hydrochloride
4
Biopsy
4
durvalumab
3
Panitumumab
3
Itraconazole
3
Epirubicin
3
Bevacizumab
3
tremelimumab
2
spartalizumab
2
ixabepilone
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Adenocarcinoma Of Esophagus
×
tegafur-gimeracil-oteracil
×
Clear all
NCT02128243
2021-03-26
MATEO
AIO-Studien-gGmbH
Phase 2
Completed
242 enrolled